# Should the Rapidly improving patient with significant vessel occlsuion be treated?

Kenneth V. Snyder, MD, PhD Assistant Professor Neurosurgery, Neurology & Radiology



Adnan H. Siddiqui, MD, PhD Elad I. Levy MD, MBA Jason Davies, MD, PhD L. N. Hopkins, MD

Gursant Atwal, MD Neuro-endovascular fellow







#### **Disclosure Statement of Financial Interest**

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

**Affiliation/Financial Relationship** 

#### Company


- Toshiba Honorarium
- Medtronic Honorarium





### **Recanalization equals better outcomes**

- Meta-analysis from 1985 2002 assessing recanalization
  - 53 studies
  - Total 2066 patients



Conclusion: Recanalization (by any means) is strongly associated with improved functional outcomes and reduced mortality





## What is the natural history of strokes that are mild or have rapidly improving symptoms?





#### Outcome of Stroke With Mild or Rapidly Improving Symptoms

Krassen Nedeltchev, MD; Benjamin Schwegler, BSc; Tobias Haefeli, MD; Caspar Brekenfeld, MD; Jan Gralla, MD; Urs Fischer, MD; Marcel Arnold, MD; Luca Remonda, MD; Gerhard Schroth, MD; Heinrich P. Mattle, MD

**Stroke 2007** 

Research Foundation

## TABLE 2. Clinical Outcome 3 Months After Stroke

	Favorable		Uniavorable				
mRS Score	0	1	2	3	4	5	6
Number (%)	72 (44)	50 (31)	26 (16)	10 (6)	<mark>2 (1)</mark>	0 (0)	2 (1)

### TABLE 4.Variables Predicting Clinical Outcome at 3 Monthsby Multivariate Analysis

Variable	Odds Ratio	95% Cl	P Value
NIHSS scale on admission $\geq 10$	16.9	1.8–159.5	0.013
Proximal vessel occlusion	7.13	1.1-45.5	0.038



Variable, n (%)	mRS 0 to 1 (n=122)	mRS 2 to 6 (n=40)	P Value
Male sex	83 (68)	27 (67)	0.71
Age, mean (SD)	62 (13)	65 (13)	
Vascular risk factors			
Hypertension	73 (60)	26 (65)	0.37
Diabetes mellitus	11 (9)	7 (18)	0.41
Current smoking	34 (28)	13 (33)	0.37
Hypercholesterolemia	79 (65)	25 (63)	0.56
Coronary artery disease	49 (40)	16 (40)	0.37
History of transient ischemic attack	25 (21)	7 (18)	0.30
History of amaurosis fugax	3 (3)	1 (3)	0.99
NIHSS scale on admission $\geq 10$	1 (1)	5 (13)	0.001
Stroke etiology			
Large artery arteriosclerosis	24 (20)	11 (28)	0.30
Small artery disease	29 (24)	6 (15)	0.24
Cardioembolism	32 (26)	12 (30)	0.64
Other determined etiology	8 (7)	1 (3)	0.33
Unknown etiology	25 (20)	9 (23)	0.80
Multiple causes	4 (3)	1 (3)	0.80
Brain imaging			
Early CT signs of cerebral ischemia	16 (17*)	9 (29†)	0.15
Dense artery sign	3 (3*)	0 (0)	0.32
Diffusion-weighted image-perfusion-weighted image mismatch	8 (15 <b>‡</b> )	4 (17§)	0.47
Proximal vessel occlusion	11 (9)	7 (18)	0.14

#### TABLE 3. Variables Predicting Clinical Outcome at 3 Months by Univariate Analyses

rdiovascular earch Foundation



## What happens to patients with LVO and low NIHSS?





## EXE Early MRI and outcomes of untreated patients with mild or improving ischemic stroke

V. Rajajee, MD; C. Kidwell, MD; S. Starkman, MD; B. Ovbiagele, MD; J.R. Alger, PhD; P. Villablanca, MD; F. Vinuela, MD; G. Duckwiler, MD; R. Jahan, MD; A. Fredieu, MD; S. Suzuki, MD; and J.L. Saver, MD

AAN 2006








Figure 1. Impact of presence of large-vessel occlusion on MR angiography on incidence of subsequent early neurologic deterioration with infarct expansion in ischemic stroke patients presenting within 6 hours of symptom onset.








Figure 2. Impact of presence of large-vessel occlusion on MR angiography on incidence of subsequent poor functional status (modified Rankin Scale score of >2) at discharge among patients with ischemic stroke presenting within 6 hours of symptom onset.

## How do patients do with thrombolysis and endovascular therapies?





### Outcome of patients with occlusions of the internal carotid artery or the main stem of the middle cerebral artery with NIHSS score of less than 5: comparison between thrombolysed and non-thrombolysed patients

Mirjam R Heldner,<sup>1</sup> Simon Jung,<sup>1,2</sup> Christoph Zubler,<sup>2</sup> Pasquale Mordasini,<sup>2</sup> Anja Weck,<sup>1</sup> Marie-Luise Mono,<sup>1</sup> Christoph Ozdoba,<sup>2</sup> Marwan El-Koussy,<sup>2</sup> Heinrich P Mattle,<sup>1</sup> Gerhard Schroth,<sup>2</sup> Jan Gralla,<sup>2</sup> Marcel Arnold,<sup>1</sup> Urs Fischer<sup>1</sup>

#### **BMJ 2015**






	Non-thrombolysed patients	Thrombolysed patients	p Value comparing the two groups
N	47	41	
Age, years (SD)	68 (14.1)	66.3 (12.9)	0.831
Women	14/47 (29.8)	19/41 (46.3)	0.110
Vascular risk factors			
Diabetes mellitus	10/47 (21.3)	9/41 (22)	0.939
Arterial hypertension	29/47 (61.7)	25/41 (61)	0.944
Current smoking	13/47 (27.7)	9/39 (23.1)	0.628
Hypercholesterolaemia	31/47 (66)	27/41 (65.9)	0.992
Coronary artery disease	8/47 (17)	7/41 (17.1)	0.995
Atrial fibrillation	8/40 (20)	14/37 (37.8)	0.083
Previous stroke	1/47 (2.1)	2/41 (4.9)	0.478
Cervical artery dissection	8/47 (17)	2/41 (4.9)	0.073
Family history of stroke	10/29 (34.5)	6/32 (18.8)	0.163
Aetiology according to TOAST criteria			0.086
Large artery disease	17/47 (36.2)	9/41 (22)	0.214
Cardioembolic	8/47 (17)	16/41 (39)	0.021
Other determined	9/47 (19.2)	3/41 (7.3)	0.107
Undetermined	3/47 (6.4)	5/41 (12.2)	0.344
Unknown	5/47 (10.6)	6/41 (14.6)	0.572
More than one potential cause	5/47 (10.6)	2/41 (4.9)	0.319
Minutes from symptom onset to hospital admission, median	258	101	<0.001
Improving symptoms before admission	22/47 (46.8)	18/40 (45)	0.866
Fluctuating symptoms before admission	15/47 (31.9)	9/40 (22.5)	0.327
Baseline NIHSS score, median (range)	3 (5)	4 (3)	<0.001
Imaging parameters			
Location of vessel occlusion			<0.001
ICA occlusion	35/47 (74.5)	12/41 (29.3)	
M1 occlusion	12/47 (25.5)	29/41 (70.7)	
MR mismatch	27/35 (77.1)	30/30 (100)	0.005
Thrombolysis type			
Intravenous rt-PA	-	15*/41 (36.6)	
Endovascular therapy	-	19/41 (46.3)	
Bridging (intravenous rt-PA followed by endovascular therapy)	—	7/41 (17.1)	


#### Table 1 Baseline characteristics and outcome of 88 patients, n (%) if not indicated otherwise

Jar ation

Table 2         Outcome of 88 patients, n (%) if not indicated otherwise				
	Non-thrombolysed patients	Thrombolysed patients	p Value comparing the two groups	
Ν	47	41		
Initial recanalisation TIMI 2–3 (DSA)	-	22/28 (78.6)		
Initial reperfusion TICI 2b-3 (DSA)	-	17/28 (60.7)		
Recanalisation TIMI 2–3 after 24 h (MRA/CTA)	4/38 (10.5)	30/38 (78.9)	<0.001	
NIHSS score after 24 h				
Median NIHSS score change (range)	0 (25)	-2 (36)	<0.001	
Increased	10/44 (22.7)	4/39 (10.3)	0.002	
Stable	23/44 (52.3)	10/39 (25.6)		
Decreased	11/44 (25)	25/39 (64.1)		
NIHSS score at discharge				
Median NIHSS score change (range)	0 (43)	-2.5 (43)	<0.001	
Increased	15/45 (33.3)	5/4 (12.5)	0.015	
Stable	10/45 (22.2)	5/40 (12.5)		
Decreased	20/45 (44.5)	30/40 (75)		
NIHSS score at 3 months				
Median NIHSS score change (range)	0 (43)	-3 (43)	<0.001	
Increased	17/41 (41.4)	6/40 (15)	<0.001	
Stable	9/41 (22)	2/40 (5)		
Decreased	15/41 (36.6)	32/40 (80)		
mRS 0–1 at 3 months	20/45 (44.4)	25/40 (62.5)	0.096	
mRS 0–2 at 3 months	30/45 (66.7)	34/40 (85)	0.050	
Survival at 3 months	42/45 (93.3)	37/40 (92.5)	0.881	
Symptomatic haemorrhage (PROACT)	0/45 (0)	2/41 (4.9)	0.134	
Asymptomatic haemorrhage (PROACT)	3/43 (7)	5/41 (12.2)	0.415	

#### Table 2. Outcome of 20 metions $n_{1}(0)$ if not indicated athennic









#### Non-thrombolysed (n=45)

■ Thrombolysed (n=40)






Table 4         Outcome of 47 patients with ICA occlusions, n (%) if not indicated otherwise				
	Non-thrombolysed patients	Thrombolysed patients	p Value comparing the two groups	
N	35	12		
NIHSS score after 24 h				
Median NIHSS score change (range)	0 (25)	-1 (11)	0.058	
Increased	7/32 (21.9)	1/11 (9.1)	0.261	
Stable	16/32 (50)	4/11 (36.4)		
Decreased	9/32 (28.1)	6/11 (54.5)		
NIHSS score at discharge				
Median NIHSS score change (range)	0 (43)	-2 (42)	0.055	
Increased	11/33 (33.3)	2/12 (16.7)	0.496	
Stable	6/33 (18.2)	2/12 (16.7)		
Decreased	16/33 (48.5)	8/12 (66.6)		
NIHSS score at 3 months				
Median NIHSS score change (range)	0 (43)	-2.5 (43)	0.042	
Increased	13/30 (43.3)	3/12 (25)	0.206	
Stable	6/30 (20)	1/12 (8.3)		
Decreased	11/30 (36.7)	8/12 (66.7)		





	Non-thrombolysed patients	Thrombolysed patients	p Value comparing the two groups
N	12	29	
NIHSS score after 24 h			
Median NIHSS score change (range)	0 (9)	-2 (36)	0.004
Increased	3/12 (25)	3/28 (10.7)	0.012
Stable	7/12 (58.3)	6/28 (21.4)	
Decreased	2/12 (16.7)	19/28 (67.9)	
NIHSS score at discharge			
Median NIHSS score change (range)	0 (40)	-3 (42)	0.001
ilncreased	4/12 (33.3)	3/28 (10.7)	0.023
Stable	4/12 (33.3)	3/28 (10.7)	
Decreased	4/12 (33.3)	22/28 (78.6)	
NIHSS score at 3 months			
Median NIHSS score change (range)	0 (40)	-3 (42)	0.001
Increased	4/11 (36.4)	3/28 (10.7)	0.007
Stable	3/11 (27.2)	1/28 (3.6)	
Decreased	4/11 (36.4)	24/28 (85.7)	

#### Table F. Outcome of 41 patients with M1 acclusions p(0/) if not indicated otherwise





## Do the risks outweigh the potential benefits of intervening?







#### Mechanical Thrombectomy in Patients with Acute Ischemic Stroke and Lower NIHSS Scores: Recanalization Rates, Periprocedural Complications, and Clinical Outcome

<sup>1</sup> J. Pfaff, <sup>1</sup>C. Herweh, <sup>1</sup>M. Pham, <sup>1</sup>S. Schönenberger, <sup>1</sup>S. Nagel, <sup>1</sup>P.A. Ringleb, <sup>1</sup>M. Bendszus, and <sup>1</sup>M. Möhlenbruch

AJNR 2016






 $\star$ 

# 484 patients were reviewed, 33 patients met criteria of NIHSS < 8 who underwent</li> intervention

- Median post procedure NIHSS 5
- Onset to groin puncture time 320 minutes
- Recanalization of TICI 2b or 3 achieved in 79%
- 2 symptomatic ICH
- mRS 0-2 63%, mRS 0-3 in 91%



	Patients (n = 33)
Age (yr) (mean) (SD)	68 (16)
Male (%)	14 (42.4)
Hypertension (%)	21 (63.6)
Diabetes mellitus (%)	4 (12.1)
Atrial fibrillation (%)	13 (39.4)
Coronary artery disease (%)	7 (21.2)
Congestive heart failure (%)	3 (9.1)
Hypercholesterolemia (%)	8 (24.2)
Previous stroke (%)	0 (24.2)
History of smoking (%)	8 (24.2)
Prestroke mRS	0 (24.2)
	20 /04 0)
0 (%) 1 (%)	28 (84.8) 2 (6.1)
2 (%) 3 (%)	1 (3) 2 (6.1)
Initial NIHSS score (median) (IQR)	5 (4-7)
CT	n = 18
	n = 15
MR imaging ASPECTS <sup>a</sup> (median) (IQR)	11 - 15
CT	10 (9–10)
MR imaging	8 (7–9) <sup>b</sup>
Time from stroke onset to imaging (min)	175 (72–279)
(median) (IQR)	1/3 (/2-2/9)
Intravenous tPA (%)	22 (66.7)
Time from stroke onset to intravenous tPA <sup>c</sup>	156 (94–238)
(min) (median) (IQR)	150 (94-250)
Time from stroke onset to groin puncture	320 (237-528)
(min) (median) (IQR)	520 (257-520)
Occlusion site	
ICA (excluding carotid T) (%)	4 (12.1)
Tandem occlusion (cervical ICA and	3 (9.1)
carotid T/M1)	5 (2.1)
Carotid T (%)	2 (6.1)
M1 (%)	17 (51.5)
M2 (%)	7 (21.2)
Collateral status	(22)
0 (%)	0
1 (%)	2 (6.1)
2 (%)	7 (21.2)
3 (%)	24 (72.7)
Thrombus length (mm)	12 (10–16)
monous tengen (min)	12 (10-10)

Patients with large vessel occlusion and improving NIH can get worse over the next 48 hours, thus early intervention is recommended with low NIHSS patients with LVO.









## Thank you! Questions?



